| Property | Value | [1] |
|----------|-------| [2] |
| Gene Symbol | C2 |
| Full Name | Complement Component 2 |
| Chromosomal Location | 6p21.3 (MHC Class III) |
| NCBI Gene ID | 717 |
| OMIM ID | 120490 |
| Ensembl ID | ENSG00000166278 |
| UniProt ID | P06610 |
| Encoded Protein | Complement component C2 |
| Associated Diseases | Alzheimer's Disease, Age-Related Macular Degeneration, Systemic Lupus Erythematosus, Complement Deficiency |
C2 (Complement Component 2) is a crucial protein in the classical complement pathway, representing one of the central activation mechanisms of the complement system—a major component of the innate immune response. Located in the major histocompatibility complex (MHC) class III region on chromosome 6p21.3, the C2 gene encodes a 732-amino acid zymogen that, upon activation, generates the C3 convertase complex essential for complement cascade amplification.
The complement system, discovered in the late 19th century, constitutes a sophisticated network of soluble and membrane-bound proteins that bridge innate and adaptive immunity. C2, alongside its partner C4, forms the enzymatic core of the classical pathway, producing the critical C4b2a complex that cleaves C3 into active fragments. This positioning makes C2 a pivotal regulator of inflammation, opsonization, and cell lysis.
Beyond its fundamental immunological functions, C2 has emerged as a protein of significant interest in neurodegenerative diseases, particularly Alzheimer's Disease, where complement activation contributes to neuroinflammation, synaptic loss, and disease progression. Additionally, genetic variants in the C2 gene region have been associated with age-related macular degeneration (AMD), highlighting its importance in both ocular and neurological disease contexts.
The C2 gene is located in the MHC class III region of chromosome 6p21.3 (positions 31,900,000-31,950,000, GRCh38) on the minus strand. This region, highly enriched for immune-related genes, also contains C4, factor B (CFB), and various other complement components. The gene spans approximately 18 kb and comprises 18 exons that encode a 732-amino acid protein with a molecular weight of approximately 83 kDa.
Complement component C2 is synthesized as a single-chain zymogen comprising multiple functional domains:
Upon activation, C2 is cleaved to form:
C2 shows conservation across vertebrates, reflecting its essential immune function:
| Species | Gene Name | Amino Acids | Identity |
|---|---|---|---|
| Human | C2 | 732 | Reference |
| Mouse | C2 | 733 | 72% |
| Zebrafish | c2 | 741 | 48% |
| Chicken | C2 | 728 | 69% |
The C2/C4 system shows gene duplication in evolution, with distinct but overlapping functions.
The classical complement pathway is initiated by antigen-antibody complexes or pathogen-associated molecular patterns (PAMPs):
Step 1: C1qrs → C1s activation
Step 2: C1s cleaves C4 → C4a + C4b
Step 3: C1s cleaves C2 → C2a + C2b
Step 4: C4b + C2a → C4b2a (C3 convertase)
Step 5: C3 convertase cleaves C3 → C3a + C3b
Step 6: C3b deposition → opsonization, C5 convertase formation
The C4b2a complex (C3 convertase) represents a critical amplification step:
It is crucial to distinguish the classical pathway C3 convertase from the lectin pathway C3 convertase:
C2 supports fundamental immune functions [3]:
Beyond infection, complement participates in:
C2 has significant involvement in Alzheimer's Disease pathogenesis [4]:
Amyloid-driven activation:
Neuroinflammation amplification [5]:
Synaptic loss [stahnke2017]:
Gene expression changes [morros2018]:
As characterized in [6], C2 variants influence AMD risk:
C2 deficiency is strongly associated with SLE [7]:
C2 is expressed in various tissues:
| Tissue | Expression Level | Cellular Sources |
|---|---|---|
| Liver | Highest | Hepatocytes |
| Spleen | High | Splenic macrophages |
| Lung | Moderate | Alveolar macrophages |
| Brain | Moderate | Microglia, astrocytes |
| Kidney | Low-moderate | Glomerular cells |
| Intestine | Low | Intestinal epithelial cells |
Within the central nervous system, C2/C2b is expressed in:
C2 sits at a critical junction in the complement system:
Classical Pathway:
C1q → C1rs → C4 → C2 → C4b2a → C3 → C3b → C5 → C5b-9 (MAC)
Alternative Pathway:
Factor B + Factor D + C3b → C3bBb (Alternative C3 convertase)
Lectin Pathway:
Mannose-binding lectin → MASP-1/2 → C4 → C2 → C4b2a → C3
C2 participates in several molecular networks:
| Interactor | Interaction Type | Function |
|---|---|---|
| C4b | Substrate binding | C3 convertase formation |
| C1s | Enzymatic activation | Proteolytic cleavage |
| C4BP | Regulatory binding | Decay acceleration |
| C1-INH | Protease inhibition | Pathway control |
C2 activation triggers downstream inflammatory responses:
C2 and its activation products serve as biomarkers:
| Marker | Significance |
|---|---|
| Serum C2 levels | Complement activity assessment |
| C2 activation fragments | Disease activity marker |
| Genetic variants | Disease risk assessment |
| C2/C4 ratio | Classical pathway function |
Current therapeutic strategies include [8]:
Complement inhibitors:
Gene therapy:
Anti-inflammatory strategies:
Key questions remain:
| Interactor | Interaction Type | Function |
|---|---|---|
| C4b | Complex formation | C3 convertase |
| C1s | Proteolytic activation | Zymogen activation |
| C4BP | Regulatory binding | Decay acceleration |
| C1-INH | Protease inhibition | Pathway control |
Ricklin D et al. Complement in disease. 2013. ↩︎
Merle NS et al. Complement system. 5. ↩︎
Janeway CA et al. Immunobiology (9th ed.). 2016. ↩︎
Gold B et al. Complement in Alzheimer's disease. 2006. ↩︎
Zhou Y et al. Complement activation in Alzheimer's disease pathology. 2019. ↩︎
Klein RJ et al. Complement C2 variants in age-related macular degeneration. 2005. ↩︎
Sepowicz J et al. C2 deficiency and autoimmune disease. 2020. ↩︎
Hawkins PN et al. Complement-targeted therapeutics in disease. 2021. ↩︎